Multianalyte Test Predicts Drug Resistance in Esophageal Cancer
|
By LabMedica International staff writers Posted on 16 Mar 2015 |
|
Image: Histopathology of esophageal carcinoma showing infiltrating nests of neoplastic cells (Photo courtesy of Dr. Elliot Weisenberg, MD).
A multianalyte algorithmic immunohistochemistry (IHC) assay accurately identifies patients with locoregional esophageal adenocarcinoma (EC) who exhibit extreme resistance to neoadjuvant chemoradiotherapy.
The test analyzes the localization of three protein biomarkers within a patient's tumor to classify the cancer as either responsive to or resistant to presurgical chemoradiotherapy and demonstrates strong accuracy and specificity in identifying patients with tumors that are unlikely to respond to standard presurgical (neoadjuvant) chemotherapy and radiation.
Scientists at Baylor College of Medicine (Houston TX, USA) and their colleagues studied archived biopsy specimens of EC which were subject to IHC examination of compartmentalized immunoreactivity of nuclear factor kappa B (NF-κB), Sonic Hedgehog (SHH), and GLI family zinc finger 1 (Gli-1), and a labeling index score was assigned to each biomarker. Pretreatment tumor biopsies were used to evaluate resistance (exCTRT) or responsiveness to (non-exCTRT) standard presurgical chemoradiotherapy (CTRT) regimens under accredited certified laboratory protocols.
According to validation studies, the DecisionDx-EC test (Castle Biosciences, Inc.; Friendswood, TX, USA) can reliably differentiate patients who are complete or partial responders to chemoradiotherapy from those who are non-responders. An initial, single center clinical validation study of 167 patients, which was used as training set for the current validation study, achieved an area under the curve (AUC) of 0.96 and an overall accuracy of 90%. The second validation, enrolled 64 patients from two independent institutions, and achieved an AUC of 0.96 and an overall accuracy of 84% for classifying which patients are likely to be highly resistant to presurgical chemotherapy treatment for esophageal cancer.
Derek Maetzold, BS, MBA, the President and CEO of Castle Biosciences, said, “Publication of these results is a culmination of our extensive program to analytically and clinically validate a new predictive test for esophageal cancer. DecisionDx-EC fits well within our strategy of developing and commercializing valuable prognostic tests that help physicians to select the most appropriate care for their patients.” The study was published on February 19, 2015, in the journal Gastrointestinal Cancer: Targets and Therapy.
Related Links:
Baylor College of Medicine
Castle Biosciences, Inc.
The test analyzes the localization of three protein biomarkers within a patient's tumor to classify the cancer as either responsive to or resistant to presurgical chemoradiotherapy and demonstrates strong accuracy and specificity in identifying patients with tumors that are unlikely to respond to standard presurgical (neoadjuvant) chemotherapy and radiation.
Scientists at Baylor College of Medicine (Houston TX, USA) and their colleagues studied archived biopsy specimens of EC which were subject to IHC examination of compartmentalized immunoreactivity of nuclear factor kappa B (NF-κB), Sonic Hedgehog (SHH), and GLI family zinc finger 1 (Gli-1), and a labeling index score was assigned to each biomarker. Pretreatment tumor biopsies were used to evaluate resistance (exCTRT) or responsiveness to (non-exCTRT) standard presurgical chemoradiotherapy (CTRT) regimens under accredited certified laboratory protocols.
According to validation studies, the DecisionDx-EC test (Castle Biosciences, Inc.; Friendswood, TX, USA) can reliably differentiate patients who are complete or partial responders to chemoradiotherapy from those who are non-responders. An initial, single center clinical validation study of 167 patients, which was used as training set for the current validation study, achieved an area under the curve (AUC) of 0.96 and an overall accuracy of 90%. The second validation, enrolled 64 patients from two independent institutions, and achieved an AUC of 0.96 and an overall accuracy of 84% for classifying which patients are likely to be highly resistant to presurgical chemotherapy treatment for esophageal cancer.
Derek Maetzold, BS, MBA, the President and CEO of Castle Biosciences, said, “Publication of these results is a culmination of our extensive program to analytically and clinically validate a new predictive test for esophageal cancer. DecisionDx-EC fits well within our strategy of developing and commercializing valuable prognostic tests that help physicians to select the most appropriate care for their patients.” The study was published on February 19, 2015, in the journal Gastrointestinal Cancer: Targets and Therapy.
Related Links:
Baylor College of Medicine
Castle Biosciences, Inc.
New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Hemoglobin Testing System
VARIANTnbs
Latest Pathology News
- New Technique Reveals Earliest Signs of Genetic Mutations
- New WHO Reporting System for Lung Cytopathology to Enhance Diagnostic Accuracy
- Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer
- Novel AI-Powered Method for Tissue Analysis Improves Understanding of Disease Pathology
- Noninvasive Technology Detects Rare Cancer Cells in Blood
- AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time
- New Tool Enables Better Classification of Inherited Disease-Causing Variants
- Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues
- New AI Tool Classifies Brain Tumors More Quickly and Accurately
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
Channels
Clinical Chemistry
view channel
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreMolecular Diagnostics
view channel
Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more
Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
The U.S. Centers for Disease Control and Prevention (CDC) has reported that respiratory diseases in the United States reached high levels during the recent autumn and winter seasons, with SARS-CoV-2 leading... Read more.jpeg "Image: Screening for prostate cancer with first-line MRI is less cost-effective than first-line PSA testing (Photo courtesy of Adobe Stock)")
First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance... Read more
Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
To improve cancer survival rates, it's crucial to understand the disease during its initial stages. Research involving data from thousands of cancer patients has uncovered exciting findings about how blood... Read moreHematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute)")
AI Tool Predicts Cancer Patients’ Response to Immunotherapy
Immune checkpoint inhibitors are a form of immunotherapy drug that enables immune cells to target and destroy cancer cells. At present, the Food and Drug Administration has approved two predictive biomarkers... Read more
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed... Read more
.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
Microbiology
view channel
POC STI Test Shortens Time from ED Arrival to Test Results
In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read moreTechnology
view channel
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
Industry
view channel
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
